Chronic Lymphocytic Leukemia

Matthew S. Davids, MD, MMSc, associate director, CLL Center, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses challenges in the frontline treatment of patients with chronic lymphocytic leukemia.

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses novel therapies in patients with relapsed/refractory chronic lymphocytic leukemia.

Matthew S. Davids, MD, MMSc, discusses methods for choosing between frontline therapies for patients with newly diagnosed chronic lymphocytic leukemia and highlights anticipated research in the field.

Matthew S. Davids, MD, MMSc, associate director, CLL Center, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses frontline treatment approaches for patients with chronic lymphocytic leukemia.

Erlene Seymour, MD, assistant professor of medicine, Karmanos Cancer Institute, Wayne State University, discusses promising combination therapies in the treatment of patients with chronic lymphocytic leukemia (CLL).

A supplemental new drug application has been filed for the combination of venetoclax and obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia who also have coexisting medical conditions.

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment options for patients with relapsed/refractory chronic lymphocytic leukemia.

Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the use of ibrutinib (Imbruvica) in treating chronic graft-versus-host disease in patients with chronic lymphocytic leukemia (CLL).

Based on the crucial role of BCL-2 family proteins in apoptosis regulation, targeting these proteins using BCL-2 inhibitors offers a potentially new therapeutic option for patients with various types of hematologic malignancies and, more recently, patients with solid tumors.

New agents in chronic lymphocytic leukemia are significantly strengthening the armamentarium, particularly next-generation BTK and PI3K inhibitors, and although toxicities remain an issue, tolerability may be improving.

The day is approaching that chemotherapy may be unnecessary for the treatment of patients with chronic lymphocytic leukemia.

Nicole Lamanna, MD, highlights the latest MURANO data in CLL, delving into the need for more studies to test the feasibility of time-limited treatment in this patient population.

Patients with relapsed/refractory chronic lymphocytic leukemia had an improved response rate with chimeric antigen receptor T-cell therapy if they also received ibrutinib.

Suman Kambhampati, MD, reflects on the emergence of data in chronic lymphocytic leukemia from the 2018 ASH Annual Meeting.

Jordan Gauthier, MD, MSc, discusses retrospective results of concurrent ibrutinib and JCAR014 and where chimeric antigen receptor T-cell research is headed for patients with chronic lymphocytic leukemia.

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses data from the 2018 ASH Annual Meeting in chronic lymphocytic leukemia (CLL).

Shagun Arora, MD, assistant clinical professor at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the use of venetoclax (Venclexta) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses frontline therapy selection in chronic lymphocytic leukemia (CLL).

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the combination of frontline ibrutinib plus obinutuzumab for the treatment of patients with chronic lymphocytic leukemia.